Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

Item
http://www.wikidata.org/entity/Q34296509
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceUpdates on mechanism of action and clinical efficacy of risedronate in osteoporosisQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesChemotherapy options in castration-resistant prostate cancerA randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.Future of bisphosphonates and denosumab for men with advanced prostate cancer.Circulating tumor cells in patients with metastatic castration resistant prostate cancer: exploratory findings at a tertiary referral hospital.Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.Patient-reported outcomes as end points and outcome indicators in solid tumours.Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.Cardiovascular toxicities of systemic treatments of prostate cancer.Bisphosphonates for advanced prostate cancer.Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
P2860

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

Item
http://www.wikidata.org/entity/Q34296509
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Randomised phase II/III study ...... rlands Prostate Study (NePro).
@ast
Randomised phase II/III study ...... rlands Prostate Study (NePro).
@en
Randomised phase II/III study ...... rlands Prostate Study (NePro).
@nl
type
label
Randomised phase II/III study ...... rlands Prostate Study (NePro).
@ast
Randomised phase II/III study ...... rlands Prostate Study (NePro).
@en
Randomised phase II/III study ...... rlands Prostate Study (NePro).
@nl
prefLabel
Randomised phase II/III study ...... rlands Prostate Study (NePro).
@ast
Randomised phase II/III study ...... rlands Prostate Study (NePro).
@en
Randomised phase II/III study ...... rlands Prostate Study (NePro).
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Randomised phase II/III study ...... rlands Prostate Study (NePro).
@en
P2093
P304
P31
P356
10.1016/J.EJCA.2012.05.014
P433
P478
P50
P577
P5875
P698
P921